IL-4, IL-10 and IL-13 in acute myelogenous leukemia

Cytokines, Cellular and Molecular Therapy

Volumn 4, Issue 3, 1998, Pages 187-198

  Bruserud, Øystein ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myelogenous leukemia; Interleukin 10; Interleukin 13; Interleukin 4

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN PRESENTATION; BLAST CELL; CELL PROLIFERATION; CYTOKINE RELEASE; HUMAN; IMMUNOCOMPETENT CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION;

CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-4; LEUKEMIA, MYELOCYTIC, ACUTE;

EID: 0031690579     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Puri RK, Structure and function of interleukin 4 and its receptor. Cancer Treat Res (1995) 80: 143-85.
2. Beckmann MP, Cosman D, Fanslow W et al, The interleukin 4 receptor: structure, function, and signal tranduction. Chem Immunol (1992) 51: 107-34.
3. Benjamin D, Interleukin 10 (IL10). Cancer Treat Res (1995) 80: 305-19.
4. McKenzie ANJ, Zurawski G, Interleukin 13: characterization and biological properties. Cancer Treat Res (1995) 80: 367-78.
5. Essayan DM, Han W-F, Li X-M et al, Clonal diversity of IL4 and IL13 expression in human allergen-specific T lymphocytes. J Allergy Clin Immunol (1996) 98: 1035-44.
6. Bruserud Ø, Pawelec G, Interleukin 13 (IL13) secretion by normal and post-transplant T lymphocytes; in vitro studies of cellular immune responses in the presence of acute leukaemia blast cells. Cancer Immunol Immunother (1997), 45: 45-52.
7. Fior R, Vita N, Raphael M et al, Interleukin 13 gene expression by malignant and EBV-transformed human B lymphocytes. Eur Cytokine Netw (1994) 5: 593-600.
8. Zurawski G, deVries JE, Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today (1994) 15: 19-26.
9. Olsson I, Gullberg U, Lantz M, Richter J, The receptors for regulatory molecules of hempoiesis. Eur J Haematol (1992) 48: 1-9.
10. Russel NH, Autocrine growth factors and leukemic hempoiesis. Blood Rev (1992) 6: 149-56.
11. + T cell clones derived early after allogeneic bone marrow transplantation. Scand J Immunol (1993) 38: 65-74.
12. Bruserud Ø, Pawelec G, Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts; studies of normal polyclonal T cells and T lymphocyte clones derived early after allogeneic bone marrow transplantation. Cancer Immunol Immunother (1996) 42: 133-40
13. Bruserud Ø, Ulvestad E, Halstensen A et al, Interleukin 4 responses in acute leukaemia patients with severe chemotherapy-induced leucopenia. Eur J Haematol (1997) 59: 269-76.
14. Bruserud Ø, Ulvestad E, Berentsen S et al, T lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia; characterization of clonogenic T cell proliferation. Scand J Immunol (1998) 47: 54-62.
15. Bruserud Ø, Cellular immune responses in acute leukemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells. Cancer Immunol Immunother, in press.
16. Tony HP, Shen B-J, Reusch P, Sebald W, Design of human interleukin 4 antagonists inhibiting interleukin 4-dependent and interleukin 13-dependent responses in T cells and B cells with high efficiency. Eur J Biochem (1994) 225: 659-65
17. Matthews DJ, Clark PA, Herbert J et al, Function of the interleukin 2 (TL2) receptor γ chain in biologic responses of X-linked severe combined immunodeficient B cells to IL2, IL4, IL13 and IL15. Blood (1995) 85: 38-42
18. Obiri NI, Debinski W, Leonard WJ, Puri RK, Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common γ chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem (1995) 270: 8797-804.
19. Zurawski SM, Chomarat P, Djossou O et al, The primary binding subunit of the human interleukin 4 receptor is also a component of the interleukin 13 receptor J Biol Chem (1995) 270: 13 869-78.
20. Zurawski SM, Vega F, Huyghe B, Zurawski G, Receptors for interleukin 13 and interleukin 4 are complex and share a novel component that functions in signal transduction. EMBO J (1993) 12: 2663-70.
21. Tan JC, Indelicato SR, Narula SK et al, Characterization of interleukin-10 receptors on human and mouse cells. J Biol Chem (1993) 268: 21 053-9.
22. Liu Y, Wei SH-Y, Ho AS-Y et al, Expression cloning and characterization of a human IL10 receptor. J Immunol (1994) 152: 1821-9.
23. Ho ASY, Liu Y, Khan TA et al, A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci USA (1993) 90: 11 267-71.
24. Weber-Nordt RM, Riley JK, Greenland AC et al, State recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin 10 receptor intracellular domain. J Biol Chem (1996) 271: 27 954-61
25. Bazan JF, Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA (1990) 87: 6934-8.
26. Greenlund AC, Farrar MA, Viviano BL, Schreiber RD, Ligand-induced IFNγ receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J (1994) 13: 1591-600.
27. Fernandez-Botran R, Soluble cytokine receptors: their role in immunoregulation. FASER J (1991) 5: 2567-74.
28. Mosley B, Beckmann MP, March CJ et al, The murine interleukin 4 receptor: molecular cloning and characterization of secreted and membrane-bound forms. Cell (1989) 59: 335-48.
29. Wrighton N, Campbell LA, Harada N et al, The murine interleukin 4 receptor gene: genomic structure, expression and potential for alternative splicing Growth Factors (1992) 6: 103-18.
30. Fernandez-Botran R, Vitetta ES, A soluble, high-affinity, IL4-binding protein is present in the biological fluids in mice. Proc Natl Acad Sci USA (1990) 87: 4202-6.
31. Maliszewski CR, Sato TA, Davison B et al, In vivo biological effects of recombinant soluble IL4 receptor. Proc Soc Exp Biol Med (1994) 206: 233-7.
32. Fanslow WC, Clifford KN, Park LS et al, Regulation of alloreactivity in vivo by IL4 and the soluble IL4 receptor. J Immunol (1991) 147: 535-40.
33. Fernandex-Botran R, Vitetta ES, Evidence that natural murine soluble IL4 receptors may act as transport proteins. J Exp Med (1991) 174: 673-81.
34. Sato TA, Widmer MB, Finkelman FD et al, Recombinant soluble murine IL4 receptor can inhibit or enhance IgE responses in vivo. J Immunol (1993) 150: 2717-23.
35. Fernandez-Botran R, Chilton PM, Ma Y et al, Control of the production of soluble interleukin 4 receptors: implications in immunoregulation. J Leukoc Biol (1996) 59: 499-504.
36. Chilton PM, Fernandez-Botran R, The production of soluble IL4 receptors by murine spleen cells is regulated by T cell activation and IL 4. J Immunol (1993) 151: 5907-17.
37. Meyer RJ, Davies RB, Schiffer CA et al, Intensive postremission therapy in adults with acute myeloid leukemia. N Engl J Med (1994) 331: 896-903.
38. Bishop JF, Matthews JP, Young GA et al, A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood (1996) 87: 1710-7.
39. van der Meer JWM, Defects in host defense mechanisms. In: Clinical Approach to Infection in the Compromised Host, 3rd edn (ed RH Rubin, LS Young) 33-66. Plenum, New York, 1994.
40. Koll BS, Brown AE, The changing epidemiology of infections at cancer hospitals. Clin Infect Dis (1993) 17(Suppl 2): S322-8.
41. Anaissie E, Opportunistic mycoses in the immunocompromised host: experience at a cancer centre and review. Clin Infect Dis (1992) 14(Suppl 1): S43-53.
42. Young LS, Management of infections in leukemia and lymphoma. In: Clinical Approach to Infection in the Compromised Host, 3rd edn (ed RH Rubin, LS Young) 551-79. Plenum, New York, 1994.
43. Burke GW, Cirocco R, Markou M et al, Early development of acute myelogenous leukemia following kidney transplantation: possible role of multiple serum cytokines. Leuk Lymphoma (1995) 19: 173-80.
44. Bruserud Ø, Halstensen A, Peen E, Solberg CO, Serum levels of adhesion molecules and cytokines in patients with acute leukaemia. Leuk Lymphoma (1996) 23: 423-30.
45. Ostermann H, Rothenburger M, Mesters RM et al, Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br J Haematol (1994) 88: 332-7.
46. Rintala E, Pulkki K, Mertsola J et al, Endotoxin, interleukin-6 and phospholipase-A2 as markers of sepsis in patients with hematological malignancies. Scand J Infect Dis (1995) 27: 39-43.
47. Steinshamn S, Brekke O-L, Waage A, Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin-6 in serum in granulocytopenic patients with fever Br J Haematol (1995) 89: 719-24.
48. Bruserud Ø, Bergheim J, Shammas FV, Nesthus I, Serum concentrations of tumor necrosis factor-α during chemotherapy-induced leucopenia in patients with acute leukaemia and bacterial infections. Leukemia Res (1994) 18: 415-21.
49. Bruserud Ø, Aasen I, Akselsen PE et al, Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapy-induced leucopenia. Eur J Haematol (1996) 57: 87-95.
50. Bruserud Ø, Akselsen PK, Bergheim J, Nesthus I, Serum concentrations of E-selectin, P-selectin, ICAM-1 and interleukin 6 in acute leukaemia patients with chemotherapy-induced leucopenia and bacterial infections. Br J Haematol (1995) 91: 394-402.
51. Südhoff T, Wehmeier A, Arning M et al, Increases of s-ICAM-1 during neutropenic pneumonia in leukemic patients. Leukemia (1997) 11: 346-51.
52. Caruso A, Licenziati S, Corulli M et al, Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry (1997) 27: 71-6.
53. Romani L, Howard DH, Mechanisms of resistance to fungal infections. Curr Opin Immunol (1995) 7: 517-23.
54. Fidel PL Jr, Sobel JD, The role of cell-mediated immunity in candidiasis. Trends Microbiol (1994) 2: 202-6.
55. Christman JW, Potential treatment of sepsis syndrome with cytokine-specific agents. Chest (1992) 102: 613-17.
56. Cheson BD, Cassileth PA, Head DR et al, Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 8: 813-19.
57. Bruserud Ø, Gjertsen BT, Brustugun OT et al, Effect of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. Leukemia (1995) 9: 1910-20.
58. Sissolak G, Hoffbrand AV, Mehta AB, Ganeshaguru K, Effects of interferon alpha (IFN) on the expression of interleukin 1 beta (IL1) interleukin 6 (IL6), granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor alpha (TNF) in acute myeloid leukemia blasts. Leukemia (1992) 6: 1155-60.
59. Fiedler W, Suciu E, Wittlief C et al, Mechanisms of growth factor expression in acute myeloid leukemia (AML). Leukemia (1990) 4: 459-61.
60. Reuss-Borst MA, Klein G, Waller HD, Müller CA, Differential expression of adhesion molecules in acute leukemia. Leukemia (1995) 9: 869-874.
61. McGlave PB, Haake RJ, Bostrom BC et al, Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood (1988) 72: 1512-17.
62. Keating S, Suciu S, deWitte T et al, Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GINEMA AML 8A trial. Bone Marrow Transplant (1996) 17: 993-1001.
63. Raza A, Maheshwari Y, Preisler HD, Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia Blood (1987) 69 1647-53.
64. Asano Y, Okamura S, Shibuya T et al, Growth of clonogenic myeloblastic cells in the presence of human recombinant hematopoietic growth factors. Blood (1988) 72: 1682-6.
65. Oster W, Cicco NA, Klein H et al, Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest (1989) 84: 451-7.
66. Vellenga E, deWolf JTM, Beentjes JAM et al, Divergent effects of interleukin 4 on the granulocyte colony-stimulating factor and IL3-supported myeloid colony-formation from normal and leukemic bone marrow cells. Blood (1990) 75: 633-7.
67. Delwel R, Salem M, Pellens C et al, Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum free culture system. Blood (1988) 72: 1944-9.
68. Braserud Ø, Effects of endogenous interleukin 1 on blast cells derived from acute myelogenous leukemia patients. Leukemia Res (1996) 20: 65-73.
69. Nara N, McCulloch EA, The proliferation in suspension of the progenitors of the blast cells in acute myeloblastic leukemia. Blood (1985) 65: 1484-93.
70. Miyauchi J, Kelleher CA, Yang Y-C et al, The effects of three recombinant growth factors, IL3, GM-CSF, and G-CSF, on blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood (1987) 70: 657-63.
71. + cells. Blood (1996) 88: 319-27.
72. Nørgaard JM, Langkjer ST, Palshof T et al, Relation of blast cell survival and proliferation to chemotherapy resistance in AML. Br J Haematol (1996) 93: 888-97.
73. Cannistra SA, Groshek P, Griffin JD, Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia (1989) 3: 328-34.
74. Heil G, Krauter J, Beyer-Johannböke E et al, CD54 expression and its role in homotypic aggregation of the blasts of acute myelogenous leukemias (AML). Int J Hematol (1994) 60: 39-49.
75. Lübbert M, Herrmann F, Koeffler HP, Expression and regulation of myeloid-specific genes in normal and leukemic myeloid cells. Blood (1991) 77: 909-24.
76. Bruserud Ø, Pawelec G, Effects of dipyridamole and r-verapamil on in vitro proliferation of blast cells derived from patients with acute myelogenous leukaemia Leukemia Res (1993) 17: 507-13.
77. Bradbury D, Zhu Y-M, Russell NH, Regulation of Bcl-2 expression and apoptosis in acute myeloblastic leukemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia (1994) 8: 786-91.
78. Zhu Y-M, Bradbury DA, Russell NH, Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukemic cells. Br J Cancer (1994) 69: 468-72.
79. Salem M, Delwel R, Touw I et al, Human AMT, colony growth in serum-free culture. Leukemia Res (1988) 12: 157-65.
80. Wagteveld AJ, Zanten AKV, Esselink MT et al, Expression and regulation of IL4 receptors on human monocytes and acute myeloblastic leukemic cells. Leukemia (1991) 5: 782-8.
81. - blasts from acute myelogenous leukemia. Blood (1991) 78: 197-204.
82. Jansen JH, Fibbe WE, Wientjens GJHM et al, Inhibitory effect of interleukin 4 on the proliferation of acute myeloid leukemia cells with myelomonocytic differentiation (AML-M4/M5); the role of interleukin 6. Leukemia (1993) 7: 643-5.
83. Miyauchi J, Clark SC, Tsunematsu Y et al, Interleukin 4 as a growth regulator of clonogenic cells in acute myelogenous leukemia in suspension culture. Leukemia (1991) 5: 108-15.
84. Wagteveld AJ, Esselink MT, Limburg P et al, The effects of EL1β and IL4 on the proliferation and endogenous secretion of growth factors by acute myeloblastic leukemic cells. Leukemia (1992) 6: 1020-4.
85. Imai Y, Tohd S, Nagata K et al, Effects of recombinant IL4 on the growth and differentiation of blast progenitors stimulated with G-CSF, GM-CSF and IL3 from acute myelogenous leukaemia patients. Br J Haematol (1991) 78: 173-9.
86. Siitonen T, Lundstöm M, Zheng A et al, Effect of mast cell growth factor on clonogenic blast cell growth in acute myelogenous leukemia Ann Hematol (1996) 73: 71-8.
87. Budel LM, Delwel R, Buitenen CV et al, Effects of mast cell growth factor on acute myeloid leukemia cells in vitro: effects of combinations with other cytokines. Leukemia (1993) 7: 426-34.
88. Imai Y, Nara N, Tohda S et al, Antiproliferative and differentiative effects of recombinant interleukin 4 on a granulocyte colony-stimulating factor-dependent myeloblastic leukemic cell line. Blood (1991) 78: 471-8.
89. Topp MS, Papadimitriou CA, Eitelbach F et al, Antiproliferative effect of human interleukin 4 in human cancer cell lines: studies of the mechanism. Leuk Lymphoma (1995) 19: 319-28.
90. Wetzler M, Estrov Z, Talpaz M et al, Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL4, IL1β and TNFα Cancer Res (1994) 54: 1837-42.
91. Bruserud Ø, Mentzoni L, Bühring H-J, Pawelec G, Effects of hematopoietic growth factors on interleukin 6 secretion by blast cells derived from acute myelogenous leukemia patients. Acta Haematol (1996) 96: 155-61.
92. Bruserud Ø, Nesthus I, Bühring H-J, Pawelec G, Cytokine modulation of interleukin 1 and tumour necrosis factor α secretion from acute myelogenous leukaemia blast cells in vitro. Leukemia Res (1995) 19: 15-22
93. Bruserud Ø, Effects of interleukin 13 on cytokine secretion by human acute myelogenous leukemia blasts. Leukemia (1996) 10: 1497-503.
94. Jansen JH, Fibbe WE, Wientjens GJHM et al, Interleukin 4 downregulates the expression of CD14 and the production of interleukin 6 in acute myeloid leukemia Lymphokine Cytokine Res (1991) 10: 457-61.
95. Rambaldi A, Torcia M, Bettoni S et al, Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin 1 receptor antagonist and lack of its expression by leukemic cells. Blood (1991) 78: 3248-53
96. Salem M, Delwell R, Mahmoud LA et al, Maturation of human acute myeloid leukaemia in vitro: the response to five recombinant haematopoietic factors in a serum-free system. Br J Haematol (1989) 71: 363-70.
97. Howell AL, Stukel TA, Bloomfield CD et al, Induction of differentiation in blast cells and leukemic colony-forming cells from patients with acute myeloid leukemia Blood (1990) 75: 721-9.
98. Leung KN, Mak NK, Fung MC, Hapel AJ, Syngergistic effect of IL4 and TNFα in the induction of differentiation of a mouse myeloid leukaemic cell line (WEHI-3B JCS). Immunology (1994) 81: 65-72.
99. Tuyt LML, Dokter WHA, Esselink MT, Vellenga E, Divergent effects of IL10 and IL4 on the proliferation and growth factor secretion by acute myeloblastic leukemic cells. Eur Cytokine Netw (1995) 6: 231-5.
100. Drexler HG, Zaborski M, Quentmee H, Cytokine response profiles of human myeloid factor-dependent leukemia cell lines. Leukemia (1997) 11: 701-8.
101. Blair A, Hogge DE, Ailles LE et al, Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood (1997) 89: 3104-12.
102. Pawelec G, Immune surveillance of leukemia: rationale for immunotherapy? Hematol Rev (1994) 8: 123-47.
103. Schultze J, Nadler LM, Gribben JG, B7-mediated costimulation and the immune response. Blood Rev (1996) 10: 111-27.
104. Davis MM, The T cell receptor gene diversity and selection. Ann Rev Biochem (1990) 59: 475-96.
105. Gluckman JC, Canque B, Chapuis F, Rosenzwajg M, In vitro generation of human dendritic cells and cell therapy. Cytokines Cell Mol Ther (1997) 3: 187-96.
106. Reid CD, Stackpoole A, Meager A, Tikerpee J, Interactions of tumour necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol (1992) 149: 2681-8.
107. Peters JH, Gieseler R, Thiele B, Steinbach F, Dendritic cells: from ontogenic orphans to myelomonocytic descendants. Immunol Today (1996) 17: 273-8.
108. Galy A, Travis M, Cen D, Chen B, Human T, B, natural killer and dendritic cells anse from a common bone marrow progenitor cell subset. Immunity (1995) 3: 459-73.
109. O'Neill HC, The lineage relationship of dendritic cells with other hematopoietic cells [editorial]. Scand J Immunol (1994) 39: 513-16
110. Romani N, Gruner S, Brang D et al, Proliferating dendritic cell progenitors in human blood. J Exp Med (1994) 180: 83-93.
111. Raspadori D, Lauria F, Ventura MA et al, Expression of adhesion molecules on acute leukemia blast cells and sensitivity to normal LAK activity. Ann Hematol (1993) 67: 213-6.
112. Shultze JL, Seamon NJ, Michalak S et al, Autologous tumor-infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood (1997) 89: 3806-16.
113. Kwak LW, Sternas LA, Jagannath S et al, T cell responses elicited by immunization of multiple myeloma patients with idiotypic M-protein plus GM-CSF in remission after autologous transplantation. Blood (1997) 90(Suppl 1): 579a.
114. Gambacorti-Passerini C, Grignani F, Arienti F et al, Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RARα present in acute promyelocytic leukemia cells. Blood (1993) 81: 1369-75.
115. Pawelec G, Max H, Halder T et al, BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood (1996) 88: 2118-24.
116. tenBosch GJA, Joosten AM, Kessler JH et al, Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood (1996) 88: 3522-7.
117. + cytotoxic T cell clones. Blood (1997) 90(Suppl 1): 199a.
118. - T cells with cytotoxic activity against leukemia cells from patients with chronic myeloid leukemia. Blood (1997) 90(Suppl 1): 198a.
119. + T cell clones derived from four leukaemia patients. Eur J Haematol (1995) 54: 106-10.
120. + T cell clones derived early after allogeneic bone marrow transplantation. Eur J Haematol (1993) 51: 73-9.
121. Pardoll DM, Paracrine cytokine adjuvants in cancer immunotherapy. Ann Rev Immunol (1995) 13: 399-415
122. Tepper RI, Pattengale PK, Leder P, Murine interleukin 4 displays potent antitumor activity in vivo. Cell (1989) 57: 503-12.
123. Golumbek PT, Lazenby AJ, Levitsky HI et al, Treatment of established renal cancer by tumor cells engineered to secrete interleukin 4. Science (1991) 254: 713-6.
124. Li WC, Diamantstein T, Blankenstein B, Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the antitumor function of interleukin 4. Mol Immunol (1990) 27: 1331-7.
125. Dranoff G, Jaffee Em, Lazenby E et al, Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long-lasting antitumor immunity. Proc Natl Acad Sci USA (1993) 90: 3539-43.
126. Huang AYC, Golumbek P, Ahmadzadeh M et al, The role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 264: 961-5.
127. Heufler C, Koch F, Schuler G, Granulocyte-macrophage colony stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med (1988) 167: 700-5.
128. Sallusto F, Lanzavecchia A, Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by ganulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med (1994) 179: 1109-18
129. + cells. Blood (1996) 88(Suppl 1): 154a.
130. Sakamoto O, Hashiyama M, Minty A et al, Interleukin 13 selectively suppresses the growth of human macrophage progenitors at the kite stage Blood (1995) 85: 3487-93.
131. Bruserud Ø, Mentzoni L, Foss B et al, Human T lymphocyte activation in the presence of acute myelogenous leukemia blasts: studies of allostimulated interferon-γ secretion. Cancer Immunol Immunother (1996) 43: 275-82.
132. Sanz MA, Sempere A, Immunophenotyping of AML and MDS and detection of residual disease. Baillière's Clin Haematol (1996) 9: 35-55.
133. Hirano N, Takahashi T, Takahashi T et al, Expression of cosumulatory molecules in human leukemias. Leukemia (1996) 10: 1168-76.
134. Strunk D, Linkesch W, Acute myelogenous leukemia cells can be differentiated into dendritic cells in vitro. Blood (1997) 90(Suppl 1): 188a.
135. Choudhury A, Agusala K, Suturia S et al, Leukemic dendritic cells derived in vitro from AML patients can stimulate antileukemic activity in autologous T cell populations. Blood (1997) 90(Suppl 1): 508a.
136. Maestroni GJM, Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res (1994) 54: 4740-3.
137. - CD11C-dendritic cell (DC) precursor: inhibition by interleukin (IL) 4 and arguments for a lymphoid DC differentiation pathway in human. Exp Hematol (1997) 25: 734.